Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  axitinib
Find trials that include:  Any drugs shown
Results 1-12 of 12 for your search:
Start Over
Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
Phase: Phase III
Type: Prevention
Age: 18 and over
Trial IDs: AP311736, NCI-2014-01024, NCT01599754
A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 105RC101, NCI-2013-01264, NCT01806064
Axitinib in Treating Patients With Stage III Malignant Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UCI 10-55, NCI-2012-02173, 2011-8282, WS830279, NCT01321437
Neoadjuvant Axitinib in Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: 2011-0231, NCI-2011-02749, NCT01409200
Axitinib in Treating Patients with Melanoma That is Metastatic or Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 197811, NCI-2011-03037, NCT01533948
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A041-04, NCI-2013-00667, ACE-041, NCT01727336
Axitinib in Treating Patients with Pheochromocytoma or Paraganglioma This is Metastatic, Recurrent or Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-C-0001, NCI-2014-02504, P11898, NCT01967576
Axitinib in Treating Patients with Neurofibromatosis Type 2 or Progressive Vestibular Schwannomas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S14-00004, NCI-2014-01039, NCT02129647
CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRLX101-208, NCI-2014-02343, NCT02187302
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A4061068, NCI-2014-00350, 2015-001724-31, NCT01999972
A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 95
Trial IDs: A4061079, NCI-2014-01997, NCT02133742
Axitinib in Treating Younger Patients with Recurrent or Refractory Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 17
Trial IDs: ADVL1315, NCI-2014-01093, NCT02164838
Start Over